NEW YORK (GenomeWeb News) – Decode Genetics said today that it has received a delisting notice from Nasdaq following the firm's announcement last week that it has filed for Chapter 11 bankruptcy protection.

Nasdaq informed Decode that it will suspend trading in the company’s common stock as of Nov. 30, 2009, and that it will file a Form 25-NSE with the US Securities and Exchange Commission to remove Decode's common stock from listing on Nasdaq, unless the company files an appeal to the Nasdaq Listing Qualifications Panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.